Supplementary Figure 3 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 3. Details of a 49 year old patient with platinum-refractory metastatic ovarian cancer and 5 previous lines of chemotherapy treated with oral pictilisib at 100mg once-daily on days 1-21 every 28 days.
Authors: Debashis Sarker, Joo Ern Ang, Richard Baird, Rebecca Kristeleit, Krunal Shah, Victor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362433373